Tirzepatide
Zepbound (Chronic weight management) · Mounjaro (Type 2 diabetes)
The dual-incretin agent producing the largest average weight reductions recorded in this class. Higher efficacy, comparable cost, and rapidly growing share of employer spend.
- Vendors covering
- 12
- Administration
- Once-weekly subcutaneous injection
- List cost
- $1,000–$1,300 per month at list, before rebates
Vendor coverage
Who prescribes Tirzepatide, and on what terms
The access column is the one that moves your budget. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
| Vendor | Access | Gating | Score | PMPM |
|---|---|---|---|---|
| Virta Health Reviews Tirzepatide Metabolic specialist | Escalation only | Diabetes or prediabetes diagnosis plus documented failure on the nutritional protocol. | 8.7 | $40–$95 |
| Omada Health Reviews Tirzepatide Coaching companion | Companion support | None from Omada. Your PBM controls access. | 8.4 | $32–$58 |
| Form Health Reviews Tirzepatide Full-service clinical | First-line | Same eligibility and step therapy as semaglutide. | 8.0 | $58–$105 |
| Twin Health Reviews Tirzepatide Metabolic specialist | Escalation only | Diabetes indication plus sensor-documented failure on earlier steps. | 7.8 | $55–$120 |
| Found Reviews Tirzepatide Full-service clinical | Escalation only | Documented inadequate response to earlier rungs. The highest bar in Found's formulary. | 7.6 | $45–$85 |
| Vida Health Reviews Tirzepatide Full-service clinical | Escalation only | Step therapy plus behavioral-health screening. | 7.5 | $38–$78 |
| Teladoc Health Reviews Tirzepatide Navigation & orchestration | First-line | Employer-configured. | 7.4 | $18–$44 |
| 9amHealth Reviews Tirzepatide Metabolic specialist | Escalation only | Documented failure on earlier rungs. | 7.3 | $34–$72 |
| Calibrate Reviews Tirzepatide Full-service clinical | First-line | Same eligibility as semaglutide. No step therapy. | 7.2 | $65–$110 |
| Transcarent Reviews Tirzepatide Navigation & orchestration | Orchestrated | Employer-configured, enforced at the orchestration layer. | 7.1 | $12–$32 |
| WeightWatchers Clinic Reviews Tirzepatide Consumer-brand clinical | First-line | Same as semaglutide. No step therapy. | 6.9 | $30–$68 |
| Noom Med Reviews Tirzepatide Consumer-brand clinical | First-line | BMI ≥ 27. No step therapy. | 6.6 | $28–$62 |
Clinical profile
How Tirzepatide works
- Mechanism
- Agonizes both GIP and GLP-1 receptors. The dual mechanism is the accepted explanation for its efficacy advantage over single-agonist GLP-1s, though the relative contribution of GIP remains debated.
- Administration
- Once-weekly subcutaneous injection.
- Titration
- Initiated at a low weekly dose with escalation approximately every four weeks. The full ladder to the highest maintenance dose runs longer than semaglutide's, extending the window in which members are on drug but not yet at target.
- Typical result
- In registrational trials, average body-weight reduction of roughly a fifth of starting weight at about 72 weeks at higher doses — the highest reported in this class. Real-world persistence gaps apply here as they do everywhere.
- List cost
- Roughly $1,000–$1,300 per month at list, before rebates
Known side effects
- Gastrointestinal effects broadly similar to other incretin agents, again concentrated in escalation
- Gallbladder events and pancreatitis reported at low rates
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
- Lean-mass loss proportional to the larger total reduction, which matters more at this efficacy level
For benefits teams
What Tirzepatide means for your budget
Higher efficacy is not automatically better economics
Greater average reduction at similar unit cost improves cost per point of weight lost. It also increases the likelihood members stay on therapy longer, which raises total spend. Model both effects; vendors will only show you the first.
Longer titration extends your exposure
A longer escalation ladder means more months of spend before a member reaches maintenance. If your program has a continuation-review gate, make sure the review point is set against this molecule's actual timeline rather than semaglutide's.
Lean mass deserves more attention here
Larger total weight reduction means larger absolute lean-mass loss. Vendors with real protein and resistance-training protocols matter more on this molecule than on lower-efficacy agents, particularly in older populations.